Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05888233 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

Study acronym: RESIST
StatusCompleted
PhasePhase 2
Started2024-09-30
View on ClinicalTrials.gov ↗
African American adults in the United States have the highest prevalence rate of high blood pressure (hypertension) and heart failure in the world. African Americans with treatment resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to Caucasians. This trial will test if administration of the xanthine oxidase inhibitor - Allopurinol (commonly used in the treatment of gout), given over a period of 8 weeks, will improve heart function, exercise ability and quality of life in African American Veterans with resistant hypertension.

Amendment history 6 changes detected by DataLookout

2026-09-05
Trial completed
2026-09-05
Primary endpoint(s) modified
WasLV end-diastolic fractional shortening, LV end-diastolic mass index, LV end-diastolic mid-wall radius to wall thickness ratio, Left ventricular end-diastolic volume index, Normalized peak early diastolic filling rate (E), Normalized peak late diastolic filling rate (A), EDV/s, Self Reported health survey for Heart Failure, Self reported Health Survey, Six minute walk test
NowLeft ventricular (LV) end-diastolic fractional shortening, Left ventricular (LV) end-diastolic mass index, Left ventricular (LV) end-diastolic mid-wall radius to wall thickness ratio, Left ventricular end-diastolic volume index, Normalized peak early diastolic filling rate (E), Normalized peak late diastolic filling rate (A), EDV/s, Self Reported health survey for Heart Failure, Self reported Health Survey, Six minute walk test
2026-07-19
Completion pushed: 2026-07-01 → 2026-08-31
2026-05-30
Trial status changed: Recruiting → Active, Not Recruiting
2026-05-30
Enrollment reduced: 50 → 40 participants
2026-05-30
Completion pushed: 2026-05-31 → 2026-07-01
Trial Details
NCT Number NCT05888233
Lead Sponsor VA Office of Research and Development
Conditions Heart Failure Preserved Ejection Fraction, Resistant Hypertension
Enrollment 40 participants
Start Date 2024-09-30
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-04